Last update 01 Nov 2024
Aviceda Therapeutics, Inc.

Aviceda Therapeutics, Inc.

Startups
|
Holding Company|
2018|
Massachusetts, United States
|
10-50
|

Overview

Basic Info

Introduction
Aviceda Therapeutics is a late-stage, pre-clinical biotech company focused on developing drugs for glyco-immune diseases. The company emphasizes the next generation of immunomodulators, leveraging glycobiology to address the innate immune system and chronic non-resolving inflammation specifically. Aviceda utilizes a cell-based high-throughput screening (HTS) platform for the rapid screening, selection, and optimization of ligands with maximum affinity and specificity for various innate immune cells. The company's product portfolio includes treatments for eye diseases (AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, respectively), as well as offerings for oncology (AVD-601), neurology (AVD-701), and fibrosis (AVD-801).

Tags

Respiratory Diseases
Eye Diseases
Other Diseases
Small molecule drug
Chemical drugs
Biological products

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug4
Unknown4
Chemical drugs3
Biological products1
Top 5 TargetCount
CFH(Complement factor H)1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
9
2
Phase 1 Clinical
Phase 2 Clinical
1
3
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
AVD-104
( CFH )
Age Related Macular Degeneration
More
Phase 2
ADV-1001
Liver Cirrhosis
More
Phase 1 Clinical
ADV-901
Pulmonary Fibrosis
More
Phase 1 Clinical
AVD-801
Neurodegenerative Diseases
More
Preclinical
AVD-901
Idiopathic Pulmonary Fibrosis
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free